PFE vs VRTV: Which Is the Better Buy?

Side-by-side comparison of Pfizer Inc. and Veritiv Corporation — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-06-20.
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
VS
Veritiv Corporation · Industrials
$169.99
-43.3% upside to fair value
Grade D
QuantHub Verdict
PFE has more upside to fair value (+2.8%). VRTV trades at a lower forward P/E (7.1x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric PFE VRTV
Current Price $25.22 $169.99
Fair Value Estimate $25.92 $96.38
Upside to Fair Value +2.8% -43.3%
Market Cap $143.7B $2.3B
Forward P/E 19.2x 7.1x
EV / EBITDA 12.3x 5.4x
Price / Sales 2.3x 0.3x
Price / FCF 15.2x 10.0x
Revenue Growth YoY +5.4% -19.0%
Gross Margin 69.3% 22.7%
Operating Margin 23.4% 5.9%
Return on Equity 8.4% 48.6%
Dividend Yield 0% 0%
FCF Yield 6.6% 9.99%
Analyst Consensus Hold Hold
Investment Thesis
PFE — Pfizer Inc.
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
VRTV — Veritiv Corporation
Veritiv Corporation operates as a distributor primarily in packaging, facility solutions, and print markets, with a business quality characterized by scale and network density rather than proprietary products or pricing power. The company has undergone significant transformation under CEO Salvatore A. Abbate, including a take-private transaction by Clayton, Dubilier & Rice in 2023 and a strategic…
Accumulation Zones
Metric PFE VRTV
Zone Low $19.44 $72.28
Zone High $22.03 $81.92
In Buy Zone? No No
← PFE Research    VRTV Research →    All Research